, Volume 7, Issue 2, pp 91-92
Date: 05 Jun 2012

New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

This is an excerpt from the content

Neuroendocrine tumor has long been considered as a rare tumor, although its prevalence makes it one of the most frequent gastrointestinal malignancies [1]. In the eighties, streptozotocin-based chemotherapy allowed substantial improvements in the management of advanced pancreatic neuroendocrine tumors (PNETs) [2, 3]. Subsequently, somatostatin analogues were shown to be useful for the control of symptomatic PNETs and also able to delay tumor progression in slow-growing midgut carcinoids [4].

Based on large double-blind randomized trials, sunitinib [5] and everolimus [6] have been approved last year for the treatment of patients with advanced well-differentiated PNETs. Both drugs significantly improve progression-free survival and provide substantial clinical benefit for patients with advanced PNETs [7, 8]. The availability of those novel drugs is now raising several questions such as the optimal patient management and best possible placement in the current armamentarium of patients with ...